6.7.10. change treatment. timing mcrpc treatment change remains matter debate mcrpc although clearly advisable start change treatment immediately men symptomatic progressing metastatic disease. preferably, treatment change precede development de novo symptoms worsening existing symptoms. although, number effective treatments increasing, head-to-head comparisons still rare, prospective data assessing sequencing available agents. therefore clear select appropriate ‘second-line‘ treatment, particular patients without hrr alterations biomarkers. positive example, however, card trial clearly established cabazitaxel better third-line treatment docetaxel pre-treated patients one arpi compared use second arpi . ecog ps used stratify patients. generally men ps 0–1 likely tolerate treatments ps > 2 less likely benefit. however, important treatment decisions individualised, particular symptoms related disease progression impacting ps. cases, trial active life-prolonging agents establish given treatment improve ps may appropriate. sequencing treatment discussed summary papers published following 2019 2022 apccc conferences .